Cheyne Capital Management (Uk) LLP Iovance Biotherapeutics, Inc. Transaction History

Cheyne Capital Management (Uk) LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$20.35 - $26.63 $508,750 - $665,750	-25,000 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$16.33 - $33.07 $408,249 - $826,750	25,000 New	25,000 $651,000
Q4 2020 Feb 10, 2021	SELL	$28.04 - $50.26 $483,690 - $866,985	-17,250 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$27.75 - $36.3 $478,687 - $626,175	17,250 New	17,250 $568,000
Q1 2020 May 07, 2020	SELL	$19.54 - $38.85 $1.56 Million - $3.11 Million	-80,000 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$17.95 - $29.41 $1.28 Million - $2.1 Million	-71,500 Reduced 47.19%	80,000 $2.21 Million
Q3 2019 Nov 12, 2019	SELL	$17.99 - $26.0 $629,650 - $910,000	-35,000 Reduced 18.77%	151,500 $2.76 Million
Q4 2018 Feb 05, 2019	SELL	$7.51 - $11.93 $101,385 - $161,055	-13,500 Reduced 6.75%	186,500 $1.65 Million
Q3 2018 Dec 21, 2018	SELL	$11.25 - $17.7 $2.25 Million - $3.54 Million	-200,000 Reduced 50.0%	200,000 $2.25 Million
Q3 2018 Nov 05, 2018	BUY	$11.25 - $17.7 $4.5 Million - $7.08 Million	400,000 New	400,000 $4.5 Million

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.28B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Cheyne Capital Management (Uk) LLP, based on Form 13F filings with the SEC.

Stay updated on Cheyne Capital Management (Uk) LLP with notifications on news.